WindhoverV2.0
Home
Home
Register
Register
Login
Log In
Schedule
Schedule
Information
Info
Attending Companies
Attendees
Contact
Contact
Help
Help
November 30-December 2, 2011The Westin Copley PlaceBoston, MA

Register Full Agenda

For every 2 paid attendees, get the 3rd FREE!


THE smartest business intelligence + 1:1 partnering = the best return on your conference investment.

TA Partnerships delivers companies offering the high-value assets that your future sales demand – plus, you’ll also meet the companies who are looking for exactly the assets you have to offer. The most active in-licensors and out-licensors will all be on hand to create future growth through investments in partnership deals.

If you attend one meeting this year, don’t waste your time picking through hundreds of irrelevant partners. Choose TA Partnerships 2011, whose pharmaceutical, biotechnology and investor attendees are the most senior-level in the business. Space is limited, so register today!



    Featured Keynote Session and Case Study

    When Bad Things Happen to Good Companies: Responding and Repositioning for Success

    In the year Perkins was elected CEO, a late-stage clinical trial of Infinity’s most advanced program failed, and share price dropped 30%. Two other programs in the portfolio faced make or break questions and the future of an important strategic partnership hung in the balance. Key additional capabilities were critical to bringing the company to the next stage of its evolution. The company needed to reprioritize programs, expand and diversify the portfolio, reaffirm an existing partnership and form a new one, as well as building out later stage capabilities. Infinity's leader offers lessons for biopharmaceutical companies large and small.

     

    Adelene Q. Perkins
    President and Chief Executive Officer
    Infinity Pharmaceuticals, Inc.

     

    Keynote Address

    Novel Technologies & Cohorts for Personalized Diagnostics & Therapies

    George Church, PhD
    Professor of Genetics
    Harvard Medical School
    Director of the Center for Computational Genetics
    Founder/Advisor to 22 companies



    Featuring lessons learned from the following speakers:

    Gary Gabrielsen
    VP, Business Development
    Astellas US LLC

     

    Uwe Schoenbeck, PhD

    Chief Scientific Officer, External R&D Innovation Worldwide Research and Development

    Pfizer

     

    Joseph McCracken

    Global Head Business Development & Licensing

    Roche Pharma Partnering

     

    Larry Deckelbaum

    Vice President, Cardiovascular Medicine

    Johnson & Johnson

     

    Elizabeth L. Bachert, PhD

    Sr. Director, Worldwide Business Development

    Pfizer Inc.

     

    John Delyani

    Head Therapeutics, Strategic Alliances

    Novartis Institutes for BioMedical Research

     

    Carole A. Wilmot, PhD
    Sr. Director, US Business Development
    Sanofi

     

    Alexander Schuth
    Head of Neuroscience Partnering
    Genentech, Inc.

     

    Alethia de León
    Global Business Development & Licensing
    Head of Search & Evaluation Neuroscience and Ophthalmics
    Novartis Pharma AG

     

    John L. Cantello, PhD
    Vice President, Business Development
    Metabolic Pathways & Cardiovascular Therapy Area Unit
    GlaxoSmithKline

     

    Jeffrey Wasserstein
    Senior Vice President, Business Development and Strategy
    Nycomed US

     

    Fernando Sallés, PhD, CLP
    Senior Director, Franchise Licensing Integrator Drug Delivery, Neuroscience and Ophthalmology
    External Scientific Affairs, Worldwide Licensing
    Merck & Co., Inc.


    Daniel J. Curran, MD

    Vice President, Corporate Development

    Millennium: The Takeda Oncology Company

     

    Ann Barry

    Executive Director, Worldwide Business Development

    Pfizer Inc.

     

    Neil S. Ryder PhD

    Executive Director, Infectious Diseases

    Novartis Institutes for BioMedical Research, Inc.

     

    Monica K. Cheng, PhD
    Associate Director Global Licensing - Commercial Opportunities & CardioMetabolic Diseases Business Development & Licensing
    Boehringer Ingelheim Pharmaceuticals, Inc.
    Inc.

     

    James Geraghty
    Senior Vice President
    Genzyme

     

    John Gustofson
    Business Development Director
    Strategic Partnering and Business Development
    Oncology and Infection
    AstraZeneca

     

    Milton H. Grannatt, PhD
    Vice President & Head, Negotiations, Respiratory & New Growth Opportunities
    Global Business Development & Licensing
    Novartis

     

    Michael C. Diem, MD
    Director, Business Development, Rare Diseases
    GlaxoSmithKline

     

    Roger J. Pomerantz, MD, F.A.C.P.
    Global Franchise Head for Infectious Diseases and Senior Vice President
    Merck & Co., Inc.

     

    John McDonald
    Vice President, Business Development
    Biogen Idec

     

    Campbell Murray, MD
    Managing Director
    Novartis Venture Funds


    What do you get for your conference investment?
  • 1:1 pre-scheduled meetings with your partners of choice
  • 65+ strategic presentations on how to build your R & D pipeline-both internally and externally
  • 25+ strategies from all the major pharma heads of BD, CEOs and investors
  • Several practical pre-conference workshops
  • 11+ networking opportunities with the most senior level executives in the biopharma business
  • 60 handpicked TOP projects in the Hottest Therapeutic Areas-Oncology, Metabolic/Cardiovascular, Neuroscience, Inflammatory/Autoimmune Diseases, Infectious Diseases (past nominees include Millennium, Myogen, Isis, Sirtris, BiPar and Kosan-all companies who went on to do big deals!)
  • View the complete history of alliances, financings and M&As, articles, pipeline data, of all participating companies. Companies in partnering software are all linked to Windhover’s Strategic Transactions, IN VIVO articles and Inteleos clinical pipeline links.
About Partnering
Click Title for More Info
Why Use Windhover Conferences Partnering Software?
  • Identify attendees to choose potential partners.
  • Search database of partnering/investing opportunities(including deal history and related articles).
  • Communicate and pre-schedule as many meetings as you wish with fellow attendees.
  • Showcase your company's innovative technology and investment/partnering interests.
2011 Important Partnering Deadlines
Last Chance for Early Bird-Rate 1 9/9/2011
Last Chance for Early Bird-Rate 2 10/31/2011
Partnering Opens (start scheduling meetings) 11/3/2011
Fill Out Your Attendee/Company Profile 11/4/2011
Last Chance for Discounted Rooms (rooms may sell out before this date) 11/8/2011


Each company profile on the TA Partnerships partnering software is linked with Windhover’s Strategic Transactions and IN VIVO articles database to help delegates conduct research on companies they might wish to meet at the conference.

The most comprehensive deals data in the industry, all completely exportable and customizable, Strategic Transactions includes alliances, financings and M&As across biopharmaceuticals, devices, diagnostics and university transfers. Better yet, it’s the only database with available analysis from Windhover’s award-winning editorial staff.

PLUS!  View clinical development details, successes, and failures of the products up for partnering!

Each product available for partnering in the conference software is now linked on the with Inteleos drug records.  We have made your research even easier by giving you all the info you need to prepare for partnering meetings.

TA Partnerships is more personalized and has the highest concentration of the right decision-makers, making it the most exclusive, personalized global partnering meeting out ther
e.

 


Register now and search your company’s and other companies’ profiles and products!

 

Register Full Agenda

For every 2 paid attendees, get the 3rd FREE!

 

For more information, please contact:
Pat Cardone at 203.840.6272 or email P.Cardone@Elsevier.com.


About Partnering


  • Brochure in Adobe PDF format. Coming Soon!
  • STAY CONNECTED
    Join our Therapeutic Area Partnerships event on
    Linked In

Conference Snapshot

  • • A uniquely focused meeting among R&D, financing and business development leadership to improve the partnering process and encourage innovative thinking about productivity and dealmaking

  • • Gain insights to pick targets and compounds likely to succeed)

  • • Identify the right drugs and the right partners

  • • Therapeutic Area challenges and opportunities: Who will win, Who won’t, and Where are you in the mix

  • • Expert advisers and strategic decision-makers help make sure your company is one of the winners

  • • Independent experts select the ten most promising clinical programs available for partnering in oncology, neuroscience, cardiovascular and metabolic, autoimmune and inflammatory, infectious disease and hot space therapeutic area tracks

  • • Discover ways to finance Innovation and innovate dealmaking

  • • What new ways of thinking can break down barriers to new medicines and how can partnering and financing drive the process?

Who Should Attend?

Biotech CEOs, Strategic Alliances, Business and Corporate Development, Commercial Analytics & Decision Support, Licensing, Global Discovery Alliance, Financial Planning & Analysis, Alliance Management, Venture Capital, Bankers & Service Providers

Here's What Past Attendees Say:

"The efforts to identify the ‘Top 10 Products Available for Partnering’ were well done. The product opportunities were well profiled and the conference provided an excellent forum for serious partnering activity."

"Top 10 idea is superb. They might not be the only products to fit the criteria, but hard to find any not deserving."

"Few conferences offer such focus and insight for partnering."

"A good opportunity to bring together a host of Business Development individuals through a common interest."

"Good overview of opportunities in the Therapeutic Areas. Good partnering opportunities present at the meeting."

"So efficient to focus on the specific TAs. Made my partnering meetings much more focused."

Sponsors


Global Sponsor

 

Campbell Alliance

 

Covance

 

Gold Industry Sponsors

 

Astellas

 

Sanofi Aventis

 

Silver Industry Sponsors

 

Scisive

 

TA Advisors

 

Cardiovascular/Metabolic Diseases

 

Cobbs Creek

 

HOT SPACE
(Women’s Health, Dermatology,
Bone & Muscle Disease, Ophthalmology
and other high value areas)

 

Wolpert Associates, Inc.

 

Infectious Diseases

 

Herndon Company

 

Neuroscience

 

NI Research

 

Oncology

 

Campbell Alliance

 

Autoimmune/Inflammatory Diseases

 

Healogix

 

 

Media Partners

 

Current Partnering

 

Innovaro Pharmalicensing

 

Association Sponsor

 

BIO

 

LES

 

Supporting Organization

 

LES

 

 

Major Supporting Publications

 

IN VIVO

Start-Up

PharmAsia News

 

EuropharmaToday.com

 

"The Pink Sheet"

"The Pink Sheet" DAILY

 

"The Pink Sheet"

 

Interested in sponsoring this event?
Contact Us

 

Elsevier Business Intelligence